Our proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.
Harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.
Formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.
Following the “Faces of CMT” photography competition run by HNF, CMTA and ECMTF and supported by Pharnext to mark Rare Disease Day 2021, find the booklet regrouping all photos submitted. Thanks again to all participants!
Find the full recording of Pharnext’s virtual R&D Day: unmet need in Charcot-Marie-Tooth Disease Type 1A, potential for PXT3003, interest of our Pleotherapy platform.
Pharnext will attend the CMT-France Annual Congress, wich is going virtual
Pharnext will attend the 16th International Congress on Neuromuscular Diseases, wich is going virtual over two weekends: 21-22 and 28-29 May
Pharnext will attend the 2021 Annual Meeting of the Peripheral Nerve Society which is going virtual over two weekends in June: 12–13 and 25–27